NSE: MAXHEALTH | BSE: 543220

Expensive Performer

Download real time

1229.40 17.80 (1.47%)

46.95% Gain from 52W Low

2.1M NSE+BSE Volume

NSE 19 Aug, 2025 3:31 PM (IST)

119,525.6

Market Cap

Market Leader

1.0

Beta 1Year

Average volatility

Max Healthcare Institute Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for MAXHEALTH, BSE:543220 Max Healthcare Institute Ltd.

Search Inside the pdf :

Max Healthcare Institute Ltd.

18 Aug 2025, 12:00AM

1229.40

1.47%

Result Update:Max Healthcare

Buy: Max Healthcare Institute Ltd.

Target

Axis Direct

We maintain a BUY rating on the stock with a TP of Rs 1,450/share, implying an upside potential of 19% from the CMP.

Max Healthcare Institute Ltd. is trading below its 30 day SMA of 1251.3

Max Healthcare Institute Ltd.

14 Aug 2025

1229.40

1.47%

Max Healthcare Institute (MAXHEALT IN) Q1FY26 Result Update ...

Buy: Max Healthcare Institute Ltd.

Target

Prabhudas Lilladhar

Max Healthcare Institute (MAXHEALT) reported healthy EBITDA growth of 23% YoY to Rs 6.14bn; in line with our estimates. The company showed phenomenal growth with ~19% EBITDA CAGR over FY22-25. We expect pick-up in the growth momentum given 1) strong expansion plans (+3700 additional beds over FY25-28E), 2) improving payor mix and 3) Bolt on acquisitions like recently added in Lucknow, Nagpur and Noida. Operational efficiency has also been commendable, especially in competitive markets like NCR. Our FY26E/27E...

Max Healthcare Institute Ltd. is trading above its 200 day SMA of 1128.2

Max Healthcare Institute Ltd.

22 May 2025

1229.40

1.47%

Max Healthcare Institute (MAXHEALT IN) Q4FY25 Result Update ...

Buy: Max Healthcare Institute Ltd.

Target

Prabhudas Lilladhar

Dwarka unit achieved break-even vs loss of Rs50mn in Q3. YoY to Rs 6.32bn; in line with our estimates. The company showed phenomenal additions. We expect pick-up in the growth momentum given 1) strong expansion plans (+3500 additional beds over FY24-27E), 2) improving payor mix and 3) Bolt on acquisitions like recently added in Lucknow, Nagpur and...

Max Healthcare Institute Ltd. is trading below its 30 day SMA of 1251.3

Max Healthcare Institute Ltd.

10 Apr 2025

1229.40

1.47%

MAX HEALTHCARE INSTITUTE LIMITED

Accumulate: Max Healthcare Institute Ltd.

Geojit BNP Paribas

Max Healthcare Institute Ltd. is trading above its 200 day SMA of 1128.2

Max Healthcare Institute Ltd.

04 Feb 2025

1229.40

1.47%

Max Healthcare | Q3FY25 Result Update

Buy: Max Healthcare Institute Ltd.

Target

Edelweiss

Bed expansion to bolster growth

Number of FII/FPI investors increased from 1093 to 1145 in Jun 2025 qtr.

Max Healthcare Institute Ltd.

01 Feb 2025

1229.40

1.47%

Result Update:Max Healthcare

Buy: Max Healthcare Institute Ltd.

Axis Direct

We maintain a BUY rating on MAXHEALTH with a target price of Rs 1,315/share, representing an upside potential of 26% from the CMP.

Max Healthcare Institute Ltd. has gained 38.89% in the last 1 Year

Max Healthcare Institute Ltd.

11 Dec 2024

1229.40

1.47%

Initiating Coverage:Max Healthcare

Buy: Max Healthcare Institute Ltd.

Axis Direct

We Initiate coverage on Max Healthcare Ltd. with a BUY rating and a target price of Rs 1,315/share, offering a 18% upside from the CMP.

Axis Direct increased Buy price target of Max Healthcare Institute Ltd. to 1450.0 on 18 Aug, 2025.

Max Healthcare Institute Ltd.

25 Nov 2024

1229.40

1.47%

MAX HEALTHCARE INS LTD

Buy: Max Healthcare Institute Ltd.

FundsIndia

Max Healthcare Institute Ltd. is trading above its 200 day SMA of 1128.2

Max Healthcare Institute Ltd.

07 Nov 2024

1229.40

1.47%

Higher patient volumes and realization drive EBITDA

Buy: Max Healthcare Institute Ltd.

Motilal Oswal

Max Healthcare (MAXH) delivered slightly better-than-expected operational performance in 2QFY25. The annualized EBITDA per bed improved to INR7.8m from INR7.0m QoQ at its existing centers.